Vaxcyte to Present at BofA Securities 2021 Health Care Conference
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the BofA Securities 2021 Health Care Conference set for May 13, 2021, at 3:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the BofA Securities 2021 Health Care Conference set for May 13, 2021, at 3:30 PM ET. The event will feature company management presenting the latest developments in their innovative vaccines aimed at combating infectious diseases. A live webcast will be accessible via their official website, with a replay available for 30 days post-conference. Vaxcyte is noted for its advanced vaccine candidates including VAX-24, addressing pneumococcal disease, and VAX-XP for broader strain coverage.
Details
News Market Reaction – PCVX
The recorded move for PCVX in the trading session of this news was +1.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 3:30pm ET.
A live webcast of the presentation can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. Vaxcyte’s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease. For more information, visit www.vaxcyte.com.
Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com
Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.